Carmex Cold Sore Treatment Claims Exceed Monograph Limit In NAD Review
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Carma Labs’ Carmex Cold Sore Treatment claims did not mirror language in two OTC monographs for its active ingredients, the National Advertising Division says in a review of packaging and advertising claims challenged by GlaxoSmithKline's consumer business.
You may also be interested in...
Mucinex Fast-Max Advertising Claim Exceeds Indications In NAD Review
Review was second in two years by the Council of Better Business Bureaus' National Advertising Division of a challenge to Reckitt Benckiser ad claims for its Mucinex cough/cold line made by Procter & Gamble, which markets competing products including Vicks NyQuil and DayQuil brands.
Athlete's Foot Firm Kicks Back On NAD Finding That Brand Is A Fungal Claim
Kramer Laboratories' claims for Fungi-Nail athlete's foot product referred to FDA and FTC after it refuses to comply with NAD's recommendation to modify the name. The firm, which agreed to modify packaging and commercial claims, was warned by FDA about the brand in 2005.
Abreva Shortened Healing Time, Duration Of Cold Sores Stressed In Promos
SmithKline Beecham's Abreva, now hitting shelves in food, drug and mass outlets, is the first OTC indicated for shortening the healing time and duration of symptoms related to cold sores and fever blisters.